# PReoperative Chemoradiation (Paclitaxel-carboplatin or FOLFOX) for Resectable Esophageal and Junctional Cancer

> **NCT02359968** · PHASE2 · COMPLETED · sponsor: **Centre Oscar Lambret** · enrollment: 106 (actual)

## Conditions studied

- Esophageal Neoplasms
- Gastro-esophageal Junction Cancer

## Interventions

- **DRUG:** FOLFOX
- **DRUG:** CarboP-pacliT

## Key facts

- **NCT ID:** NCT02359968
- **Lead sponsor:** Centre Oscar Lambret
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-02-26
- **Primary completion:** 2021-01-08
- **Final completion:** 2024-02-09
- **Target enrollment:** 106 (ACTUAL)
- **Last updated:** 2026-03-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02359968

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02359968, "PReoperative Chemoradiation (Paclitaxel-carboplatin or FOLFOX) for Resectable Esophageal and Junctional Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02359968. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*